The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
JNK signalling in cancer: in need of new, smarter therapeutic targets
Open accessAbstract
The JNKs are master protein kinases that regulate many physiological processes, including inflammatory responses, morphogenesis, cell proliferation, differentiation, survival and death. It is increasingly apparent that persistent activation of JNKs is involved in cancer development and progression. Therefore, JNKs represent attractive targets for therapeutic intervention with small molecule kinase inhibitors. However, evidence supportive of a tumour suppressor role for the JNK proteins has also been documented. Recent studies showed that the two major JNK proteins, JNK 1 and JNK 2, have distinct or even opposing functions in different types of cancer. As such, close consideration of which JNK proteins are beneficial targets and, more importantly, what effect small molecule inhibitors of JNKs have on physiological processes, are essential. A number of ATP‐competitive and ATP‐non‐competitive JNK inhibitors have been developed, but have several limitations such as a lack of specificity and cellular toxicity. In this review, we summarize the accumulating evidence supporting a role for the JNK proteins in the pathogenesis of different solid and haematological malignancies, and discuss many challenges and scientific opportunities in the targeting of JNKs in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Signal transduction by the JNK group of MAP kinases
Davis, R. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00116-1 · Cited by 4,237
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
A central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Signal integration by JNK and p38 MAPK pathways in cancer development
Wagner, E. F., & Nebreda, Á. R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2694 · Cited by 2,586
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558 · cited 8×
“MAPKs are activated via a BJP British Journal ofPharmacology DOI:10.1111/bph.12432 www.brjpharmacol.org 24 British Journal of Pharmacology (2014) 171 24–37 © 2013 The British Pharmacological Society kinase signalling cascade in which a MAP3K activates a MAP2K, that in turn activates a MAPK.”
BackgroundInfluential
Cited by
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
Extracellular ATP and P2 purinergic signalling in the tumour microenvironment
Di Virgilio, F., Sarti, A. C., Falzoni, S., De Marchi, E., & Adinolfi, E. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0037-0 · Cited by 723
The ERK and JNK pathways in the regulation of metabolic reprogramming
Papa, S., Choy, P. M., & Bubici, C. (2019) · Oncogene · doi:10.1038/s41388-018-0582-8 · Cited by 381
Self-citationThorsell, A.-G., Ekblad, T., Karlberg, T., Löw, M., Pinto, A. F., Trésaugues, L., Moche, M., Cohen, M. S., & Schüler, H. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00990 · Cited by 358
JNK signaling in cancer cell survival
Wu, Q., Wu, W., Fu, B., Shi, L., Wang, X., & Kuca, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21574 · Cited by 322
The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review
Liu, K., Zheng, M., Lu, R., Du, J., Zhao, Q., Li, Z., Li, Y., & Zhang, S. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01304-w · Cited by 287
The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer
Hammouda, M., Ford, A., Liu, Y., & Zhang, J. (2020) · Cells · doi:10.3390/cells9040857 · Cited by 284
Ramsdale, R., Jorissen, R. N., Li, F. Z., Al-Obaidi, S., Ward, T., Sheppard, K. E., Bukczynska, P. E., Young, R. J., Boyle, S. E., Shackleton, M., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aab1111 · Cited by 143
Regulation of human trophoblast gene expression by endogenous retroviruses
Frost, J. M., Amante, S. M., Okae, H., Jones, E. M., Ashley, B., Lewis, R. M., Cleal, J. K., Caley, M. P., Arima, T., Maffucci, T., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-00960-6 · Cited by 94
Role of JNK signaling in oral cancer: A mini review
Gkouveris, I., & Nikitakis, N. G. (2017) · Tumor Biology · doi:10.1177/1010428317711659 · Cited by 87
JNK signaling is converted from anti- to pro-tumor pathway by Ras-mediated switch of Warts activity
Enomoto, M., Kizawa, D., Ohsawa, S., & Igaki, T. (2015) · Developmental Biology · doi:10.1016/j.ydbio.2015.05.001 · Cited by 74
Jiang, C., Zhu, Y., Chen, H., Lin, J., Xie, R., Li, W., Xue, J., Chen, L., Chen, X., & Xu, S. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06181-5 · Cited by 36
JNK pathway in osteosarcoma: pathogenesis and therapeutics
Li, Y.-S., Deng, Z.-H., Zeng, C., & Lei, G.-H. (2016) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2015.1122045 · Cited by 31
Metadata
- Authors
- Bubici, C., & Papa, S.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2013-12-10
- Volume
- 171
- Issue
- 1
- Pages
- 24-37
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1598771153
- Cited by
- 346
- References
- 135
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.